Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.
Por:
Gonzalez-Cao, M, de las Casas, C, Oramas, J, Berciano-Guerrero, M, De la Cruz, L, Cerezuela-Fuentes, P, Arance, A, Munoz-Couselo, E, Espinosa, E, Puertolas, T, Beveridge, R, Ochenduszko, S, Silva, M, Basterretxea, L, Bellido, L, Rodriguez-Abreu, D, Drozdowskyj, A, Vila, M, Lopez-Martin, J and Berrocal, A
Publicada:
20 may 2021
Resumen:
Filiaciones:
Inst Oncol Dr Rosell, Barcelona, Spain.
Pangaea Oncol, Barcelona, Spain.
Hosp Univ Canarias, Tenerife, Spain.
HURyVV Hosp Univ Reg & Virgen Victoria Malaga, Unidad Intercentros Oncol, IBIMA Inst Invest Biomed Malaga, Malaga, Spain.
Hosp Univ Virgen Macarena, Seville, Spain.
Hosp Virgen Arrixaca, Med Oncol, Murcia, Spain.
Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain.
Vall dHebron Inst Oncol, Vall dHebron Hosp, Barcelona, Spain.
La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain.
Hosp Miguel Servet, Med Oncol, Zaragoza, Spain.
Hosp Univ & Politec La Fe, Valencia, Spain.
Hosp Univ Dr Peset, Valencia, Spain.
Complexo Hosp Univ Vigo, Vigo, Spain.
Hosp Univ Donostia, San Sebastian, Spain.
Hosp Univ Salamanca, Salamanca, Spain.
Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain.
Hosp Univ Dexeus, Inst Oncol Dr Rosell, Dept Oncol, Barcelona, Spain.
Hosp 12 Octubre, Madrid, Spain.
Hosp Gen Univ Valencia, Valencia, Spain.
|